<p>In this episode of, <a href="https://www.linkedin.com/in/ACoAACTNR0IBsp1EedwihQRhKZqyi6ftuvfkSlQ?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACTNR0IBsp1EedwihQRhKZqyi6ftuvfkSlQ" target="_blank" rel="ugc noopener noreferrer">Daniel Evans</a> , HEOR Associate at FIECON, speaks with Charlotte Keys, a patient advocate, whose son Lucas was diagnosed with Citrullinaemia Type 1, and <a href="https://www.linkedin.com/in/ACoAACMaFXsBa-NE6oJGfffgL199JMY8uy-kbrM?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACMaFXsBa-NE6oJGfffgL199JMY8uy-kbrM" target="_blank" rel="ugc noopener noreferrer">Jonathan Alexander Gibson</a>, Campaigns Lead at <a href="https://www.linkedin.com/company/metabolic-support-uk/" target="_blank" rel="ugc noopener noreferrer">Metabolic Support UK</a> . 

</p>

In this episode of, Daniel Evans , HEOR Associate at FIECON, speaks with Charlotte Keys, a patient advocate, whose son Lucas was diagnosed with Citrullinaemia Type 1, and Jonathan Alexander Gibson, Campaigns Lead at Metabolic Support UK .

<p>In this episode of, <a href="https://www.linkedin.com/in/ACoAACTNR0IBsp1EedwihQRhKZqyi6ftuvfkSlQ?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACTNR0IBsp1EedwihQRhKZqyi6ftuvfkSlQ" rel="noopener noreferrer">Daniel Evans</a> , HEOR Associate at FIECON, speaks with Charlotte Keys, a patient advocate, whose son Lucas was diagnosed with Citrullinaemia Type 1, and <a href="https://www.linkedin.com/in/ACoAACMaFXsBa-NE6oJGfffgL199JMY8uy-kbrM?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACMaFXsBa-NE6oJGfffgL199JMY8uy-kbrM" rel="noopener noreferrer">Jonathan Alexander Gibson</a>, Campaigns Lead at <a href="https://www.linkedin.com/company/metabolic-support-uk/" rel="noopener noreferrer">Metabolic Support UK</a> . 

</p>

The patient journey | Citrullinaemia Type 1

In our series of podcasts, FIECON team members engage with patient advocates and thought leaders to explore the burden, unmet needs, patient journey, and potential future treatments for specific diseases, with the aim of gaining a deeper understanding of the patient's perspective, particularly for rare diseases.
 
At FIECON, we are dedicated to ensuring that life-changing treatments reach the patients who truly need them, while also increasing awareness and amplifying the patient voice to make a meaningful difference.

Science

Life Sciences

In our series of podcasts, FIECON team members engage with patient advocates and thought leaders to explore the burden, unmet needs, patient journey, and potential future treatments for specific diseases, with the aim of gaining a deeper understanding of the patient's perspective, particularly for rare diseases. At FIECON, we are dedicated to ensuring that life-changing treatments reach the patients who truly need them, while also increasing awareness and amplifying the patient voice to make a meaningful difference.

Share The patient journey | Citrullinaemia Type 1

Sign up to save your podcasts

The patient journey | Citrullinaemia Type 1

The patient journey | Citrullinaemia Type 1